Fact check
AI analysis“A new DNA test can diagnose brain tumors in hours.”
Reasoning
Several primary sources (Nature article, FDA 510(k) clearance, Tempus press release) describe a DNA‑based liquid‑biopsy test that can return brain‑tumor diagnostic results within 3–5.8 hours. Contrasting primary sources (Clinical Cancer Research, AACR statement) argue that no platform has yet demonstrated reliable hour‑scale turnaround in everyday clinical practice, emphasizing the need for broader validation. The claim is therefore supported by early‑phase evidence but remains unproven in widespread clinical use.
On confidence: Peer‑reviewed data and FDA clearance report sub‑6‑hour turnaround, but independent experts note the lack of large‑scale, routine‑clinical validation.
Important context
The test analyzes tumor‑specific DNA mutations in cerebrospinal fluid using rapid sequencing. Reported sensitivities (~92%) and specificities (~95%) come from pilot or early‑phase cohorts. FDA clearance pertains to the device’s intended use, not necessarily its performance across diverse settings.
Evidence
Supporting (4)
- Tier 1 — Primary sourceRapid cell-free DNA sequencing of cerebrospinal fluid for diagnosis of brain tumors
The assay achieved a median turnaround time of 5.8 hours from sample receipt to result, enabling same‑day diagnosis of brain tumors.
- Tier 1 — Primary sourceFDA 510(k) clearance for RapidBrainDx DNA test
The device is indicated for detection of tumor‑specific DNA mutations in cerebrospinal fluid with results available within 4 hours.
- Tier 1 — Primary sourceTempus launches 3‑hour DNA test for brain tumor diagnosis
Our new assay delivers diagnostic results in under 3 hours with 92% sensitivity and 95% specificity in a pilot cohort.
- Tier 2 — Independent reportingindependent originRapid DNA test for brain tumors shows promise in early trials
Early‑phase trials indicate the assay can identify tumor DNA within 4 hours with high specificity, suggesting potential for same‑day diagnosis.
Contradicting (2)
- Tier 1 — Primary sourceChallenges of liquid biopsy for central nervous system tumors
Current DNA‑based assays for brain tumors typically require 24–48 h processing, and no platform has yet demonstrated reliable sub‑6‑hour turnaround in routine clinical practice.
- Tier 1 — Primary sourceAACR statement on rapid DNA diagnostics for brain tumors
While promising, DNA tests for brain tumor detection have not yet achieved diagnostic turnaround within hours in validated clinical settings.
Contextual (1)
- Tier 2 — Independent reportingindependent originNew test may spot brain tumors in hours, but experts urge caution
The test, developed by Tempus, can deliver results in three hours, yet researchers say larger studies are needed to confirm accuracy and real‑world feasibility.
Limitations
Evidence is limited to early trials and manufacturer‑reported data; independent, large‑scale studies are lacking. Real‑world feasibility, reproducibility, and regulatory acceptance beyond the clearance are not yet established.
- Last verified:
- Sep 26, 2026, 5:11 PM CDT
- Pipeline:
- 0.1.0
- Claim type:
- Factual
Where this claim appeared
The Download: the Pentagon’s AI-powered lie detector and young organ limitsMIT Technology Review